Lactulose


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Hepatic encephalopathy
Adult: As 3.335 g/5 mL solution: Initially, 30-45 mL 3-4 times daily, may be adjusted as necessary to achieve 2 or 3 soft stools daily.

Oral
Constipation
Adult: As 3.335 g/5 mL solution or 10 g/15 mL single dose solution sachet: Initially, 15-45 mL (10-30 g or 1-3 sachets) daily, may be adjusted according to clinical response. Maintenance dose: 15-30 mL (10-20 g or 1-2 sachets) daily. All doses may be given as a single daily dose or in 2 divided doses. Therapeutic effect may occur after 2-3 days of treatment. As powder for solution: 10-20 g daily, may increase to 40 g daily if necessary.
Child: <1 year As 3.335 g/5 mL solution: Initially, up to 5 mL daily. Maintenance dose: Up to 5 mL daily. 1-6 years As 3.335 g/5 mL solution: Initially, 5-10 mL daily. Maintenance dose: 5-10 mL daily. 7-14 years As 3.335 g/5 mL solution or 10 g/15 mL single dose solution sachet: Initially, 15 mL (10 g or 1 sachet) daily, may be adjusted according to clinical response. Maintenance dose: 10-15 mL (10 g or 1 sachet) daily. >14 years Same as adult dose. All doses may be given as a single daily dose or in 2 divided doses.

Rectal
Hepatic encephalopathy
Adult: Mix 200 g (300 mL) of solution with 700 mL of water or 0.9% NaCl: Administer as a retention enema via balloon catheter over 30-60 minutes, may be repeated every 4-6 hourly depending on the response to treatment or until oral administration is possible.
Cách dùng
May be taken with or without food. May be taken w/ meals to reduce GI discomfort. Dilute w/ water, milk, or fruit juice to improve taste.
Hướng dẫn pha thuốc
Powder for oral solution: Dissolve contents of a packet labelled as 10 g or 20 g in approx 120 mL of water. Refer to specific product guidelines.
Chống chỉ định
Galactosaemia, gastrointestinal obstruction or subocclusive syndromes, acute inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease); existing or at risk of gastrointestinal perforation, painful abdominal syndromes of an unknown cause; patient requiring a low galactose diet.
Thận trọng
Patient with lactose intolerance, diabetes mellitus, gastro-cardiac syndrome (Roemheld syndrome); undergoing electrocautery procedures during proctoscopy or colonoscopy. Not recommended for use in patients with rare hereditary problems of galactose or fructose intolerance, the total lactase deficiency or glucose-galactose malabsorption. Reconsider dose and/or other additional measures if insufficient therapeutic effect is observed. Debilitated patients. Infants, children, and elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Electrolyte imbalance, diarrhoea (long-term treatment or excessive doses).
Gastrointestinal disorders: Nausea, vomiting, flatulence, abdominal pain.
Metabolism and nutrition disorders: Dehydration.
Thông tin tư vấn bệnh nhân
Drink sufficient amounts of fluids (1.5-2 L or 6-8 glasses daily).
Chỉ số theo dõi
Evaluate painful abdominal symptoms of an unknown cause prior to treatment initiation. Monitor blood pressure, serum electrolytes, serum ammonia, fluid status, and bowel movement frequency/consistency.
Quá liều
Symptoms: Diarrhoea, loss of electrolyte, abdominal pain. Management: Symptomatic treatment. Administer fluid and electrolyte replacement as necessary for extensive fluid loss caused by diarrhoea or vomiting.
Tương tác
May diminish the therapeutic effect with glutamine. May increase the risk of K loss caused by thiazides, corticosteroids, and amphotericin B. May increase the effects of cardiac glycosides. Non-absorbable antacids, neomycin, or other anti-infectives may cause a decrease in the desired effect of treatment with lactulose.
Tác dụng
Description: Lactulose, is a synthetic disaccharide osmotic laxative. Through bacterial degradation it is converted to low molecular organic acids; these acids cause a decrease of pH in the colonic lumen, and through an osmotic effect, an increase of the volume of colonic contents. Collectively, these effects cause peristalsis of the colon and the normalisation of stool consistency. In hepatic encephalopathy, its effect has been associated to the inhibition of proteolytic bacteria by an increase of acidophilic bacteria, trapping of ammonia in the ionic form through the acidification of the colonic contents, catharsis caused by the osmotic effect and the low pH in the colon, and the alteration of the bacterial nitrogen metabolism by promoting the utilisation of ammonia for bacterial protein synthesis.
Onset: Constipation: Up to 24-48 hours. Hepatic encephalopathy: At least 24-48 hours.
Pharmacokinetics:
Absorption: Poorly absorbed from the gastrointestinal tract.
Metabolism: Metabolised by colonic bacterial flora into low molecular organic acids (mainly lactic acid and small amounts of formic and acetic acids).
Excretion: Mainly via faeces; urine (≤3% as unchanged drug).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Lactulose, CID=11333, https://pubchem.ncbi.nlm.nih.gov/compound/Lactulose (accessed on Jan. 22, 2020)

Bảo quản
Store between 15-30°C. Protect from light. Do not refrigerate or freeze.
Phân loại MIMS
Thuốc nhuận trường, thuốc xổ
Phân loại ATC
A06AD11 - lactulose ; Belongs to the class of osmotically acting laxatives.
Tài liệu tham khảo
Anon. Lactulose. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 08/03/2022.

Anon. Lactulose. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/03/2022.

Buckingham R (ed). Lactulose. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2022.

Constulose Solution (Actavis Pharma, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 08/03/2022.

Duphalac (Mylan Products Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 08/03/2022.

Joint Formulary Committee. Lactulose. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2022.

Kristalose Powder for Solution (Cumberland Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 08/03/2022.

Lactulose Solution (Fresenius Kabi Austria GmbH). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 08/03/2022.

Laevolac 10 g/15 mL Oral Solution Sachets (Fresenius Kabi Austria GmbH). MHRA. https://products.mhra.gov.uk. Accessed 08/03/2022.

Nophalac Solution 670 mg/mL (Norpharma Sdn. Bhd.). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 24/03/2022.

Unilac (Kck Pharmaceutical Industries Sdn. Bhd.). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 24/03/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Lactulose từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Laevolac
  • Lufogel
  • Razolax
  • YSP Lactul
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in